株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界におけるタンパク薬物の市場・製造技術:血液因子・ワクチン・ペプチド抗体への注目

Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Blood Factors, Vaccines and Peptide Antibiotics

発行 BCC Research 商品コード 289316
出版日 ページ情報 英文 183 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: BCC Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
世界におけるタンパク薬物の市場・製造技術:血液因子・ワクチン・ペプチド抗体への注目 Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Blood Factors, Vaccines and Peptide Antibiotics
出版日: 2013年10月31日 ページ情報: 英文 183 Pages
概要

当レポートでは、世界のタンパク薬物/治療市場について詳細に分析し、さまざまな病気の治療における重要なツールとしての包括的な分析と将来の方向性を示しており、将来の戦略、市場成長の促進因子と阻害因子、タンパク治療薬の分類・製造工程・利用、産業構造、地域・種類・製造手法別の収益内訳、各分類における売上の実績と5カ年予測、および主要企業のプロファイルなどを提供し、概略下記の構成でお届けいたします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • 定義
  • 歴史
  • 治療用タンパク質の薬理学的分類
  • 製造技術
  • 治療用タンパク質の分子分類
    • サイトカイン
    • 抗体
    • 血液製剤
    • ペプチド抗体
    • ワクチン
    • 酵素
    • ペプチドホルモン

第4章 規制状況

  • モノクロナール抗体
  • 治療用酵素
  • サイトカイン
  • ワクチン
  • 血液因子
  • ペプチドホルモン
  • 新薬承認申請/生物学的製剤承認申請
  • リコール
  • 安全上の注意事項

第5章 新規開発

  • 血液製剤
  • ワクチン
  • ペプチドホルモン
  • ペプチド抗生物質
  • サイトカイン
  • モノクロナール抗体
  • 治療用酵素

第6章 世界市場

  • 市場:種類別
    • 市場概要
    • 市場収益
    • 市場シェア
  • 市場:地域別
    • 市場概要
    • 市場収益
    • 市場シェア
    • ペプチドホルモン・治療用酵素市場
    • サイトカイン・モノクロナール抗体市場
    • 血液因子・ワクチン・ペプチド抗体市場
  • 市場:製造工程別
    • 市場概要
    • 市場収益
    • 市場シェア

第7章 血液因子・ワクチン・ペプチド抗体

  • 市場:種類別
    • 市場概要
    • 市場収益
    • 市場シェア
    • 血液因子市場
    • ワクチン市場
    • ペプチド抗体市場
  • 市場:地域別
    • 血液因子市場
    • ワクチン市場
    • ペプチド抗体市場
  • 市場:製造工程別
    • 血液因子市場
    • ワクチン市場
    • ペプチド抗体市場
  • 市場:産業構造別
    • 血液因子市場
    • ワクチン市場
    • ペプチド抗体市場
  • 第8章 特許分析
  • 特許:年度別
  • 特許:種類/分類別
  • 特許:企業別
  • 特許:国別
  • 特許:出願者別

第9章 現況

  • タンパク質治療市場の影響因子
    • 慢性疾患の有病率の増加
    • 人口高齢化の拡大
    • ライフスタイルの変化
    • 新製品発売
    • 製造技術の進歩
    • 価格統制
    • 規制圧力
    • 後続生物製剤/バイオシミラーの参入
    • M&A
    • ライセンシング合意

第10章 企業プロファイル

第11章 付録

図表リスト

目次
Product Code: BIO134A

REPORT HIGHLIGHTS

This report provides:

  • An overview of the markets for major classes of protein with a focus on blood factors, vaccines, and peptide antibiotics.
  • Analyses of market trends, with data from 2011 and 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) for the period 2013 to 2018.
  • Examinations of current successes, including size and sales forecasts for this segment over the next five years.
  • Discussion of the regulatory environment, technological developments and their related strengths and weaknesses, as well as discussion on growing competition and changing customer needs.

STUDY OBJECTIVES

The objective of BCC in conducting this study is to provide an overview of the current and future characteristics of the global market for protein drugs/therapeutics. The key objective is to present a comprehensive analysis and future direction of protein drugs as an important tool in the treatment of various diseases.

This report explores present and future strategies within the protein therapeutics market, which includes peptide hormones, therapeutic enzymes, cytokines, monoclonal antibodies, blood factors, vaccines and peptide antibodies. The improvisation of the market, the setbacks and the needs of the market are discussed in this report. The classifications, manufacturing processes and usage of protein drugs are also portrayed.

A detailed analysis of protein therapeutics industry structure has been conducted. Revenues are broken down by region, by type and by manufacturing method. Sales figures are given for 2011, 2012 and estimated for the five-year period from 2013 through 2018.

The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THIS STUDY

Widespread research in the field of protein therapeutics has discovered specific functionality that provides therapeutic treatments for various diseases.

R&D spending, along with increasing competition, patent expiries and new technologies are providing a new direction. New advancements, new product launches and a changing lifestyle have caused the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of each type of technology in light of the new technologies, growing competition, and changing customer needs.

ABOUT THE AUTHOR

A team of professionals in the biotechnology industry carried out this study. The project manager is Shalini S Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ABOUT THE AUTHOR
  • RELATED BCC RESEARCH REPORTS
  • BCC ONLINE SERVICES
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: GLOBAL REVENUE OF PROTEIN THERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL REVENUE OF PROTEIN THERAPEUTICS MARKET, 2011-2018 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • DEFINITIONS
  • HISTORY
    • TABLE 1: EVOLUTION OF THERAPEUTIC PROTEINS
  • PHARMACOLOGICAL CLASSIFICATION OF THERAPEUTIC PROTEINS
    • PROTEIN THERAPEUTICS WITH ENZYMATIC OR REGULATORY ACTIVITY
    • PROTEIN THERAPEUTICS WITH SPECIAL TARGETED ACTIVITY
    • PROTEIN VACCINES
  • MANUFACTURING TECHNOLOGIES
    • NATURAL SOURCING AND EXTRACTION
      • TABLE 2: PROTEIN DRUGS MADE BY HUMAN SOURCE EXTRACTION
      • TABLE 3: PROTEIN DRUGS MADE BY ANIMAL SOURCE EXTRACTION
    • MICROBIAL FERMENTATION
      • TABLE 4: PROTEIN DRUGS MADE BY MICROBIAL FERMENTATION
    • TRANSGENICS
      • TABLE 5: PROTEIN DRUGS MADE BY TRANSGENIC ORGANISMS
    • MAMMALIAN CELL CULTURE
      • TABLE 6: PROTEIN DRUGS MADE BY MAMMALIAN CELL CULTURE
    • OTHER CELL CULTURE SYSTEMS
      • TABLE 7: PROTEIN DRUGS MADE BY INSECT CELL CULTURE
  • MOLECULAR CLASSIFICATION OF THERAPEUTIC PROTEINS
    • CYTOKINES
      • Colony-stimulating Factors
      • Interferons
      • Interleukins
    • ANTIBODIES
    • BLOOD PRODUCTS
      • Alpha-1- Proteinase Inhibitor
      • Antihemophilic Factor
      • Antithrombin
      • C1 Esterase Inhibitor
      • Coagulation Factors
      • Immuno-Globulins
      • Protein C
      • Thrombin
    • PEPTIDE ANTIBIOTICS
    • VACCINES
    • ENZYMES
      • Digestive Enzymes
      • Lysosomal Enzymes
      • Thrombolytic Enzymes
      • Other Enzymes
    • PEPTIDE HORMONES
      • Follicle-stimulating Hormone and Luteinizing Hormone
      • Adrenocorticotropic Hormone
      • Growth Hormones
      • Erythropoietin
      • Insulin

CHAPTER 4 - REGULATORY ASPECTS

  • MONOCLONAL ANTIBODIES
    • TABLE 8: NEW APPROVALS OF MONOCLONAL ANTIBODIES (2009-JUNE 2013)
  • THERAPEUTIC ENZYMES
    • TABLE 9: NEW APPROVALS OF THERAPEUTIC ENZYMES (2009-JUNE 2013)
  • CYTOKINES
    • TABLE 10: NEW APPROVALS OF CYTOKINES (2009-JUNE 2013)
  • VACCINES
    • TABLE 11: NEW APPROVALS OF VACCINES (2009-JUNE 2013)
  • BLOOD FACTORS
    • TABLE 12: NEW APPROVALS OF BLOOD FACTORS (2009-JUNE 2013)
  • PEPTIDE HORMONES
    • TABLE 13: NEW APPROVALS OF PEPTIDE HORMONES (2009- JUNE 2013)
  • NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS
    • TABLE 14: NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS (2009-JUNE 2013)
  • RECALLS
    • TABLE 15: RECALLS (2009-JUNE 2013)
  • SAFETY ALERTS
    • TABLE 16: SAFETY ALERTS (2009-JUNE 2013)

CHAPTER 5 - NEW DEVELOPMENTS

  • BLOOD PRODUCTS
    • TABLE 17: NEW DEVELOPMENTS/CLINICAL TRIALS IN BLOOD PRODUCTS
  • VACCINES
    • TABLE 18: NEW DEVELOPMENTS/CLINICAL TRIALS IN VACCINES
  • PEPTIDE HORMONES
    • TABLE 19: NEW DEVELOPMENTS/CLINICAL TRIALS IN PEPTIDE HORMONES
  • PEPTIDE ANTIBIOTICS
    • TABLE 20: NEW DEVELOPMENTS/CLINICAL TRIALS IN PEPTIDE ANTIBIOTICS
  • CYTOKINES
    • TABLE 21: NEW DEVELOPMENTS/CLINICAL TRIALS IN CYTOKINES
  • MONOCLONAL ANTIBODIES
    • TABLE 22: NEW DEVELOPMENTS/CLINICAL TRIALS IN MONOCLONAL ANTIBODIES
  • THERAPEUTIC ENZYMES
    • TABLE 23: NEW DEVELOPMENTS/CLINICAL TRIALS IN ENZYMES

CHAPTER 6 - GLOBAL MARKETS

  • MARKETS BY TYPE
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 24: GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY TYPE, THROUGH 2018 ($ MILLIONS)
      • FIGURE 1: GLOBAL MARKET FOR PROTEIN THERAPEUTICS, BY TYPE, THROUGH 2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 25: MARKET SHARE OF PROTEIN THERAPEUTICS, BY TYPE, 2012 (%)
      • FIGURE 2: MARKET SHARE OF PROTEIN THERAPEUTICS, BY TYPE, 2012 (%)
  • MARKET BY REGION
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 26: GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY REGION, THROUGH 2018 ($ MILLIONS)
      • FIGURE 3: GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY REGION, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 27: MARKET SHARE OF PROTEIN THERAPEUTICS, BY REGION, 2012 (%)
      • FIGURE 4: MARKET SHARE OF PROTEIN THERAPEUTICS, BY REGION, 2012 (%)
  • MARKET FOR PEPTIDE HORMONES AND THERAPEUTIC ENZYMES
    • Market Overview
    • Market Revenue
      • TABLE 28: GLOBAL MARKET FOR PEPTIDE HORMONES AND THERAPEUTIC ENZYMES BY REGION, THROUGH 2018 ($ MILLIONS)
      • FIGURE 5: GLOBAL MARKET FOR PEPTIDE HORMONES AND THERAPEUTIC ENZYMES BY REGION, 2011-2018 ($ MILLIONS)
    • Market Share
      • TABLE 29: MARKET SHARE OF PEPTIDE HORMONES AND THERAPEUTIC ENZYMES BY REGION, 2012 (%)
      • FIGURE 6: MARKET SHARE OF PEPTIDE HORMONES AND THERAPEUTIC ENZYMES BY REGION, 2012 (%)
  • MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES
    • Market Overview
    • Market Revenue
      • TABLE 30: GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 ($ MILLIONS)
      • FIGURE 7: GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 ($ MILLIONS)
    • Market Share
      • TABLE 31: MARKET SHARE OF MONOCLONAL ANTIBODIES BY REGION, 2012 (%)
      • FIGURE 8: MARKET SHARE OF MONOCLONAL ANTIBODIES BY REGION, 2012 (%)
  • MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS
    • Market Overview
    • Market Revenue
      • TABLE 32: GLOBAL MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS BY REGION, THROUGH 2018 ($ MILLIONS)
      • FIGURE 9: GLOBAL MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS BY REGION, 2011-2018 ($ MILLIONS)
    • Market Share
      • TABLE 33: MARKET SHARE OF BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS BY REGION, 2012 (%)
      • FIGURE 10: MARKET SHARE OF BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS BY REGION, 2012 (%)
  • MARKET BY MANUFACTURING PROCESS
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 34: GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 ($ MILLIONS)
      • FIGURE 11: GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 35: MARKET SHARE OF PROTEIN THERAPEUTICS BY TYPE OF MANUFACTURING PROCESS, 2012 (%)
      • FIGURE 12: MARKET SHARE OF PROTEIN THERAPEUTICS BY TYPE OF MANUFACTURING PROCESS, 2012 (%)

CHAPTER 7 - BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS

  • MARKET BY TYPE
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 36: GLOBAL MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 13: GLOBAL MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 37: MARKET SHARE OF BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS, 2012 (%)
      • FIGURE 14: MARKET SHARE OF BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS, 2012 (%)
  • MARKET FOR BLOOD FACTORS
    • Market Overview
    • Market Revenue
      • TABLE 38: GLOBAL MARKET FOR BLOOD FACTORS BY TYPE, THROUGH 2018 ($ MILLIONS)
      • FIGURE 15: GLOBAL MARKET FOR BLOOD FACTORS BY TYPE, THROUGH 2018 ($ MILLIONS)
    • Market Share
      • TABLE 39: MARKET SHARE OF BLOOD FACTORS, BY TYPE, 2012 (%)
      • FIGURE 16: MARKET SHARE OF BLOOD FACTORS, BY TYPE, 2012 (%)
  • MARKET FOR VACCINES
    • Market Overview
    • Market Revenue
      • TABLE 40: GLOBAL MARKET FOR VACCINES BY TYPE, THROUGH 2018 ($ MILLIONS)
      • FIGURE 17: GLOBAL MARKET FOR VACCINES BY TYPE, 2011-2018 ($ MILLIONS)
    • Market Share
      • TABLE 41: MARKET SHARE OF VACCINES BY TYPE, 2012 (%)
      • FIGURE 18: MARKET SHARE OF VACCINES BY TYPE, 2012 (%)
  • MARKET FOR PEPTIDE ANTIBIOTICS
    • Market Overview
    • Market Revenue
      • TABLE 42: GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY TYPE, THROUGH 2018 ($ MILLIONS)
      • FIGURE 19: GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY TYPE, 2011-2018 ($ MILLIONS)
    • Market Share
      • TABLE 43: MARKET SHARE OF PEPTIDE ANTIBIOTICS BY TYPE, 2012 (%)
      • FIGURE 20: MARKET SHARE OF PEPTIDE ANTIBIOTICS BY TYPE, 2012 (%)
  • MARKET BY REGION
    • BLOOD FACTORS
      • Market Overview
      • Market Revenue
        • TABLE 44: GLOBAL MARKET FOR BLOOD FACTORS BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 21: GLOBAL MARKET FOR BLOOD FACTORS BY REGION, 2011-2018 ($ MILLIONS)
      • Market Share
        • TABLE 45: MARKET SHARE OF BLOOD FACTORS, BY REGION, 2012 (%)
        • FIGURE 22: MARKET SHARE OF BLOOD FACTORS, BY REGION, 2012 (%)
  • VACCINES
    • Market Overview
    • Market Revenue
      • TABLE 46: GLOBAL MARKET FOR VACCINES BY REGION, THROUGH 2018 ($ MILLIONS)
      • FIGURE 23: GLOBAL MARKET FOR VACCINES BY REGION, 2011-2018 ($ MILLIONS)
    • Market Share
      • TABLE 47: MARKET SHARE OF VACCINES BY REGION, 2012 (%)
      • FIGURE 24: MARKET SHARE OF VACCINES BY REGION, 2012 (%)
  • PEPTIDE ANTIBIOTICS
    • Market Overview
    • Market Revenue
      • TABLE 48: GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY REGION, THROUGH 2018 ($ MILLIONS)
      • FIGURE 25: GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY REGION, 2011-2018 ($ MILLIONS)
    • Market Share
      • TABLE 49: MARKET SHARE OF PEPTIDE ANTIBIOTICS BY REGION, 2012 (%)
      • FIGURE 26: MARKET SHARE OF PEPTIDE ANTIBIOTICS BY REGION, 2012 (%)
  • MARKET BY MANUFACTURING PROCESS
    • BLOOD FACTORS
      • Market Overview
      • Market Revenue
        • TABLE 50: GLOBAL MARKET FOR BLOOD FACTORS BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 ($ MILLIONS)
        • FIGURE 27: GLOBAL MARKET FOR BLOOD FACTORS BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 ($ MILLIONS)
      • Market Share
        • TABLE 51: MARKET SHARE OF BLOOD FACTORS BY TYPE OF MANUFACTURING PROCESS, 2012 (%)
        • FIGURE 28: MARKET SHARE OF BLOOD FACTORS BY TYPE OF MANUFACTURING PROCESS, 2012 (%)
  • VACCINES
    • Market Overview
    • Market Revenue
      • TABLE 52: GLOBAL MARKET FOR VACCINES BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 ($ MILLIONS)
      • FIGURE 29: GLOBAL MARKET FOR VACCINES BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 ($ MILLIONS)
    • Market Share
      • TABLE 53: MARKET SHARE OF VACCINES, BY TYPE OF MANUFACTURING PROCESSES, 2012 (%)
      • FIGURE 30: MARKET SHARE OF VACCINES, BY TYPE OF MANUFACTURING PROCESSES, 2012 (%)
  • PEPTIDE ANTIBIOTICS
    • Market Overview
    • Market Revenue
      • TABLE 54: GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 ($ MILLIONS)
      • FIGURE 31: GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 ($ MILLIONS)
    • Market Share
      • TABLE 55: MARKET SHARE OF PEPTIDE ANTIBIOTICS, BY TYPE OF MANUFACTURING PROCESSES, 2012 (%)
      • FIGURE 32: MARKET SHARE OF PEPTIDE ANTIBIOTICS, BY TYPE OF MANUFACTURING PROCESSES, 2012 (%)
  • INDUSTRY STRUCTURE
    • BLOOD FACTORS
      • Market Leaders
        • TABLE 56: LEADING MANUFACTURERS OF THERAPEUTIC BLOOD PRODUCTS
      • Market Share
        • TABLE 57: MARKET SHARE OF BLOOD FACTOR MANUFACTURING COMPANIES, 2012 (%)
        • FIGURE 33: MARKET SHARE OF BLOOD FACTOR MANUFACTURING COMPANIES, 2012 (%)
    • VACCINES
      • Market Leaders
        • TABLE 58: LEADING MANUFACTURERS OF VIRAL VACCINES
      • Market Share
        • TABLE 59: MARKET SHARE OF VACCINE MANUFACTURING COMPANIES, 2012 (%)
        • FIGURE 34: MARKET SHARE OF VACCINES MANUFACTURING COMPANIES, 2012 (%)
  • PEPTIDE ANTIBIOTICS
    • Market Leaders
      • TABLE 60: LEADING MANUFACTURERS OF PEPTIDE ANTIBIOTICS
    • Market Share
      • TABLE 61: MARKET SHARE OF PEPTIDE ANTIBIOTIC MANUFACTURING COMPANIES, 2012 (%)
      • FIGURE 35: MARKET SHARE OF PEPTIDE ANTIBIOTIC MANUFACTURING COMPANIES, 2012 (%)

CHAPTER 8 - PATENT ANALYSIS

  • PATENTS BY YEAR
    • TABLE 62: NUMBER OF SIGNIFICANT PATENTS, BY YEAR, JANUARY 2009-JUNE 2013
    • FIGURE 36: NUMBER OF SIGNIFICANT PATENTS, BY YEAR, JANUARY 2009-JUNE 2013
  • PATENTS BY TYPE/CATEGORY
    • TABLE 63: PATENTS BY CATEGORY, JANUARY 2009-JUNE 2013
    • FIGURE 37: PATENTS BY CATEGORY, JANUARY 2009-JUNE 2013
  • PATENTS BY COMPANY
    • TABLE 64: NUMBER OF U.S. PATENTS, BY COMPANY, JANUARY 2009- JUNE 2013
  • PATENTS BY COUNTRY
    • TABLE 65: NUMBER OF U.S. PATENTS, BY COUNTRY, JANUARY 2009-JUNE 2013
    • TABLE 66: PATENT SHARES, BY COUNTRY, JANUARY 2009-JUNE 2013 (%)
  • PATENTS BY ASSIGNEE
    • TABLE 67: NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009-JUNE 2013
    • FIGURE 38: NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009-JUNE 2013

CHAPTER 9 - CURRENT SITUATION

  • FACTORS AFFECTING THE PROTEIN THERAPEUTICS MARKET
    • INCREASING PREVALENCE OF CHRONIC DISEASES
    • GROWING AGING POPULATION
    • LIFESTYLE CHANGES
    • NEW PRODUCT LAUNCHES
    • ADVANCEMENTS IN MANUFACTURING TECHNOLOGIES
    • PRICE CONTROLS
    • REGULATORY PRESSURES
    • ENTRY OF FOLLOW-ON-BIOLOGICS/BIOSIMILARS
    • MERGERS AND ACQUISITIONS
    • LICENSING AGREEMENTS

CHAPTER 10 - COMPANY PROFILES

  • ABBOTT LABORATORIES
  • AFFYMAX
  • ALCON
  • ALEXION PHARMACEUTICALS
  • ALLERGAN INC
  • AMGEN
  • BAXTER HEALTHCARE
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BIO PRODUCTS LABORATORY
  • BIOGEN IDEC
  • BIOTEST PHARMACEUTICALS CORPORATION
  • BOEHRINGER INGELHEIM
  • BRISTOL-MYERS SQUIBB
  • BTG INTERNATIONAL LIMITED
  • CANGENE CORPORATION
  • CSL LIMITED
  • DENDREON COPORATION
  • EISAI CO. LTD.
  • ELI LILLY
  • FERRING PHARMACEUTICALS
  • FRESENIUS KABI USA
  • GLAXOSMITHKLINE
  • GRIFOLS BIOLOGICALS INC
  • HOFFMAN-LA-ROCHE
  • HOSPIRA
  • JANSSEN-CILAG
  • JOHNSON & JOHNSON
  • KAMADA LTD.
  • KEDRION BIOPHARMACEUTICALS, SPA
  • LUNDBECK LLC
  • MEDIMMUNE LLC
  • MERCK & CO, INC
  • MERCK KGAA
  • MYLAN INC.
  • NABI BIOPHARMACEUTICALS (NOW BIOTA PHARMACEUTICALS)
  • NOVARTIS
  • NOVO NORDISK INC
  • OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES.M.B.H
  • OMRIX BIOPHARMACEUTICALS LTD
  • PFIZER INC
  • PROTEIN SCIENCES CORPORATION
  • RARE DISEASE THERAPEUTICS INC.
  • REVO BIOLOGICS
  • SANDOZ
  • SANOFI
  • SEATTLE GENETICS INC.
  • SPECTRUM PHARMACEUTICALS INC.
  • TAKEDA PHARMACEUTICALS
  • UCB COMPANY
  • UPSHER SMITH LABORATORIES INC
  • VIROPHARMA INC
  • WATSON LABS
  • WOCKHARDT LIMITED
  • X-GEN PHARMS
  • ZYMOGENETICS, INC

CHAPTER 11 - APPENDIX: ABBREVIATIONS

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL REVENUE OF PROTEIN THERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS)
    • TABLE 1: EVOLUTION OF THERAPEUTIC PROTEINS
    • TABLE 2: PROTEIN DRUGS MADE BY HUMAN SOURCE EXTRACTION
    • TABLE 3: PROTEIN DRUGS MADE BY ANIMAL SOURCE EXTRACTION
    • TABLE 4: PROTEIN DRUGS MADE BY MICROBIAL FERMENTATION
    • TABLE 5: PROTEIN DRUGS MADE BY TRANSGENIC ORGANISMS
    • TABLE 6: PROTEIN DRUGS MADE BY MAMMALIAN CELL CULTURE
    • TABLE 7: PROTEIN DRUGS MADE BY INSECT CELL CULTURE
    • TABLE 8: NEW APPROVALS OF MONOCLONAL ANTIBODIES (2009--JUNE 2013)
    • TABLE 9: NEW APPROVALS OF THERAPEUTIC ENZYMES (2009--JUNE 2013)
    • TABLE 10: NEW APPROVALS OF CYTOKINES (2009--JUNE 2013)
    • TABLE 11: NEW APPROVALS OF VACCINES (2009--JUNE 2013)
    • TABLE 12: NEW APPROVALS OF BLOOD FACTORS (2009--JUNE 2013)
    • TABLE 13: NEW APPROVALS OF PEPTIDE HORMONES (2009- JUNE 2013)
    • TABLE 14: NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS (2009-JUNE 2013)
    • TABLE 15: RECALLS (2009-JUNE 2013)
    • TABLE 16: SAFETY ALERTS (2009-JUNE 2013)
    • TABLE 17: NEW DEVELOPMENTS/CLINICAL TRIALS IN BLOOD PRODUCTS
    • TABLE 18: NEW DEVELOPMENTS/CLINICAL TRIALS IN VACCINES
    • TABLE 19: NEW DEVELOPMENTS/CLINICAL TRIALS IN PEPTIDE HORMONES
    • TABLE 20: NEW DEVELOPMENTS/CLINICAL TRIALS IN PEPTIDE ANTIBIOTICS
    • TABLE 21: NEW DEVELOPMENTS/CLINICAL TRIALS IN CYTOKINES
    • TABLE 22: NEW DEVELOPMENTS/CLINICAL TRIALS IN MONOCLONAL ANTIBODIES
    • TABLE 23: NEW DEVELOPMENTS/CLINICAL TRIALS IN ENZYMES
    • TABLE 24: GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY TYPE, THROUGH 2018 ($ MILLIONS)
    • TABLE 25: MARKET SHARE OF PROTEIN THERAPEUTICS, BY TYPE, 2012 (%)
    • TABLE 26: GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 27: MARKET SHARE OF PROTEIN THERAPEUTICS, BY REGION, 2012 (%)
    • TABLE 28: GLOBAL MARKET FOR PEPTIDE HORMONES AND THERAPEUTIC ENZYMES BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 29: MARKET SHARE OF PEPTIDE HORMONES AND THERAPEUTIC ENZYMES BY REGION, 2012 (%)
    • TABLE 30: GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 31: MARKET SHARE OF MONOCLONAL ANTIBODIES BY REGION, 2012 (%)
    • TABLE 32: GLOBAL MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 33: MARKET SHARE OF BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS BY REGION, 2012 (%)
    • TABLE 34: GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 ($ MILLIONS)
    • TABLE 35: MARKET SHARE OF PROTEIN THERAPEUTICS BY TYPE OF MANUFACTURING PROCESS, 2012 (%)
    • TABLE 36: GLOBAL MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS, THROUGH 2018 ($ MILLIONS)
    • TABLE 37: MARKET SHARE OF BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS, 2012 (%)
    • TABLE 38: GLOBAL MARKET FOR BLOOD FACTORS BY TYPE, THROUGH 2018 ($ MILLIONS)
    • TABLE 39: MARKET SHARE OF BLOOD FACTORS, BY TYPE, 2012 (%)
    • TABLE 40: GLOBAL MARKET FOR VACCINES BY TYPE, THROUGH 2018 ($ MILLIONS)
    • TABLE 41: MARKET SHARE OF VACCINES BY TYPE, 2012 (%)
    • TABLE 42: GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY TYPE, THROUGH 2018 ($ MILLIONS)
    • TABLE 43: MARKET SHARE OF PEPTIDE ANTIBIOTICS BY TYPE, 2012 (%)
    • TABLE 44: GLOBAL MARKET FOR BLOOD FACTORS BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 45: MARKET SHARE OF BLOOD FACTORS, BY REGION, 2012 (%)
    • TABLE 46: GLOBAL MARKET FOR VACCINES BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 47: MARKET SHARE OF VACCINES BY REGION, 2012 (%)
    • TABLE 48: GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 49: MARKET SHARE OF PEPTIDE ANTIBIOTICS BY REGION, 2012 (%)
    • TABLE 50: GLOBAL MARKET FOR BLOOD FACTORS BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 ($ MILLIONS)
    • TABLE 51: MARKET SHARE OF BLOOD FACTORS BY TYPE OF MANUFACTURING PROCESS, 2012 (%)
    • TABLE 52: GLOBAL MARKET FOR VACCINES BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 ($ MILLIONS)
    • TABLE 53: MARKET SHARE OF VACCINES, BY TYPE OF MANUFACTURING PROCESSES, 2012 (%)
    • TABLE 54: GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 ($ MILLIONS)
    • TABLE 55: MARKET SHARE OF PEPTIDE ANTIBIOTICS, BY TYPE OF MANUFACTURING PROCESSES, 2012 (%)
    • TABLE 56: LEADING MANUFACTURERS OF THERAPEUTIC BLOOD PRODUCTS
    • TABLE 57: MARKET SHARE OF BLOOD FACTOR MANUFACTURING COMPANIES, 2012 (%)
    • TABLE 58: LEADING MANUFACTURERS OF VIRAL VACCINES
    • TABLE 59: MARKET SHARE OF VACCINE MANUFACTURING COMPANIES, 2012 (%)
    • TABLE 60: LEADING MANUFACTURERS OF PEPTIDE ANTIBIOTICS
    • TABLE 61: MARKET SHARE OF PEPTIDE ANTIBIOTIC MANUFACTURING COMPANIES, 2012 (%)
    • TABLE 62: NUMBER OF SIGNIFICANT PATENTS, BY YEAR, JANUARY 2009--JUNE 2013
    • TABLE 63: PATENTS BY CATEGORY, JANUARY 2009-JUNE 2013
    • TABLE 64: NUMBER OF U.S. PATENTS, BY COMPANY, JANUARY 2009- JUNE 2013
    • TABLE 65: NUMBER OF U.S. PATENTS, BY COUNTRY, JANUARY 2009-JUNE 2013
    • TABLE 66: PATENT SHARES, BY COUNTRY, JANUARY 2009-JUNE 2013 (%)
    • TABLE 67: NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009-JUNE 2013

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL REVENUE OF PROTEIN THERAPEUTICS MARKET, 2011-2018 ($ MILLIONS)
    • FIGURE 1: GLOBAL MARKET FOR PROTEIN THERAPEUTICS, BY TYPE, THROUGH 2018 ($ MILLIONS)
    • FIGURE 2: MARKET SHARE OF PROTEIN THERAPEUTICS, BY TYPE, 2012 (%)
    • FIGURE 3: GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 4: MARKET SHARE OF PROTEIN THERAPEUTICS, BY REGION, 2012 (%)
    • FIGURE 5: GLOBAL MARKET FOR PEPTIDE HORMONES AND THERAPEUTIC ENZYMES BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 6: MARKET SHARE OF PEPTIDE HORMONES AND THERAPEUTIC ENZYMES BY REGION, 2012 (%)
    • FIGURE 7: GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 8: MARKET SHARE OF MONOCLONAL ANTIBODIES BY REGION, 2012 (%)
    • FIGURE 9: GLOBAL MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 10: MARKET SHARE OF BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS BY REGION, 2012 (%)
    • FIGURE 11: GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 ($ MILLIONS)
    • FIGURE 12: MARKET SHARE OF PROTEIN THERAPEUTICS BY TYPE OF MANUFACTURING PROCESS, 2012 (%)
    • FIGURE 13: GLOBAL MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS, 2011-2018 ($ MILLIONS)
    • FIGURE 14: MARKET SHARE OF BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS, 2012 (%)
    • FIGURE 15: GLOBAL MARKET FOR BLOOD FACTORS BY TYPE, THROUGH 2018 ($ MILLIONS)
    • FIGURE 16: MARKET SHARE OF BLOOD FACTORS, BY TYPE, 2012 (%)
    • FIGURE 17: GLOBAL MARKET FOR VACCINES BY TYPE, 2011-2018 ($ MILLIONS)
    • FIGURE 18: MARKET SHARE OF VACCINES BY TYPE, 2012 (%)
    • FIGURE 19: GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY TYPE, 2011-2018 ($ MILLIONS)
    • FIGURE 20: MARKET SHARE OF PEPTIDE ANTIBIOTICS BY TYPE, 2012 (%)
    • FIGURE 21: GLOBAL MARKET FOR BLOOD FACTORS BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 22: MARKET SHARE OF BLOOD FACTORS, BY REGION, 2012 (%)
    • FIGURE 23: GLOBAL MARKET FOR VACCINES BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 24: MARKET SHARE OF VACCINES BY REGION, 2012 (%)
    • FIGURE 25: GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 26: MARKET SHARE OF PEPTIDE ANTIBIOTICS BY REGION, 2012 (%)
    • FIGURE 27: GLOBAL MARKET FOR BLOOD FACTORS BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 ($ MILLIONS)
    • FIGURE 28: MARKET SHARE OF BLOOD FACTORS BY TYPE OF MANUFACTURING PROCESS, 2012 (%)
    • FIGURE 29: GLOBAL MARKET FOR VACCINES BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 ($ MILLIONS)
    • FIGURE 30: MARKET SHARE OF VACCINES, BY TYPE OF MANUFACTURING PROCESSES, 2012 (%)
    • FIGURE 31: GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 ($ MILLIONS)
    • FIGURE 32: MARKET SHARE OF PEPTIDE ANTIBIOTICS, BY TYPE OF MANUFACTURING PROCESSES, 2012 (%)
    • FIGURE 33: MARKET SHARE OF BLOOD FACTOR MANUFACTURING COMPANIES, 2012 (%)
    • FIGURE 34: MARKET SHARE OF VACCINES MANUFACTURING COMPANIES, 2012 (%)
    • FIGURE 35: MARKET SHARE OF PEPTIDE ANTIBIOTIC MANUFACTURING COMPANIES, 2012 (%)
    • FIGURE 36: NUMBER OF SIGNIFICANT PATENTS, BY YEAR, JANUARY 2009--JUNE 2013
    • FIGURE 37: PATENTS BY CATEGORY, JANUARY 2009--JUNE 2013
    • FIGURE 38: NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009--JUNE 2013
Back to Top